Mochi Health: Company Overview, Business Model, and Clinical Evidence

What Mochi Health Actually Does

Mochi Health operates a direct-to-patient telehealth platform focused on obesity and metabolic health. Patients complete an online intake form, upload relevant labs or medical history, and are matched with a licensed physician who evaluates candidacy for GLP-1 receptor agonists or related medications. The platform handles prior authorizations for patients with qualifying insurance.

This model reflects a broader shift in obesity medicine. The Endocrine Society's 2024 clinical practice guideline recommends pharmacotherapy for adults with a BMI of 30 or greater, or a BMI of 27 or greater with weight-related comorbidities [1]. By lowering access barriers (no in-person visit, no referral chain), Mochi targets the roughly 42.4% of U.S. adults classified as having obesity according to CDC NHANES 2017-2020 data [2]. The company earns revenue through consultation fees, medication margins on cash-pay prescriptions, and insurance reimbursement for covered visits. Mochi also provides compounded semaglutide formulations for patients who cannot access or afford brand-name drugs, a practice that gained traction during the FDA-recognized shortage of semaglutide that began in 2022 [3].

The Medications Mochi Health Prescribes

Mochi's formulary centers on GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide. These are not fringe compounds. Semaglutide 2.4 mg weekly produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo in the STEP-1 trial (N=1,961) [4]. Tirzepatide at its highest dose (15 mg) achieved 22.5% weight reduction in the SURMOUNT-1 trial (N=2,539) at 72 weeks [5].

Mochi physicians may prescribe brand-name Wegovy or Zepbound when insurance covers them. For uninsured or underinsured patients, compounded semaglutide offers a lower-cost entry point. The FDA has permitted compounding of semaglutide during its shortage period, though the agency issued updated guidance in late 2024 clarifying that compounders must meet strict quality standards under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act [3].

Beyond GLP-1s, some Mochi providers prescribe adjunctive medications like metformin (shown to produce modest weight loss of 2-3% in non-diabetic populations [6]) or topiramate when clinically appropriate. The specific medication depends on the patient's metabolic profile, comorbidities, and insurance formulary.

Pricing and Insurance: How Mochi Health Makes Money

The business model has two revenue tracks. The first is insurance-based care, where Mochi bills the patient's plan for provider consultations and supports prior authorization for branded GLP-1s. The second is a cash-pay pathway where patients pay directly for consultations and compounded medications.

Cash-pay pricing for compounded semaglutide through platforms like Mochi typically ranges from $250 to $399 per month, depending on dose and formulation. Brand-name Wegovy carries a list price of approximately $1,349 per month without insurance [7], making the cost gap between compounded and brand-name options significant. Mochi's consultation fees generally run $50 to $99 per visit.

Insurance acceptance is a differentiator. Many telehealth weight loss competitors operate on a purely cash-pay basis. Mochi's willingness to manage prior authorizations and bill insurance directly addresses a real barrier: a 2023 KFF analysis found that only 25% of large employers covered GLP-1 medications for weight loss [8]. For patients with favorable coverage, out-of-pocket costs through Mochi can drop to copay-level amounts.

Is Mochi Health Legit? Evaluating Clinical Credibility

Legitimacy in telehealth obesity care depends on three factors: prescriber qualifications, clinical protocols, and medication sourcing. Mochi's providers are U.S.-licensed physicians or nurse practitioners operating under physician supervision, a standard model for telehealth platforms. The company states it follows the Endocrine Society and American Association of Clinical Endocrinology (AACE) guidelines for obesity pharmacotherapy [1].

Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has noted that "telehealth can meaningfully expand access to evidence-based obesity treatment, but only when paired with longitudinal follow-up and metabolic monitoring" [9]. This observation applies directly to platforms like Mochi: the quality of care depends on whether providers actually track lab values, adjust doses appropriately, and screen for contraindications rather than simply rubber-stamping prescriptions.

Red flags to watch for in any telehealth obesity platform include: no lab work requirements, guaranteed prescriptions before evaluation, and no mention of contraindication screening. Mochi's published intake process includes a health questionnaire and requests for recent labs, which aligns with guideline-concordant care. The AACE's 2024 obesity algorithm recommends baseline fasting glucose, HbA1c, lipid panel, and hepatic function tests before initiating GLP-1 therapy [10].

A legitimate concern across all telehealth GLP-1 platforms, not unique to Mochi, involves compounded medication quality. The FDA has warned consumers about risks associated with compounded semaglutide products that may not contain the same active ingredient as FDA-approved versions [3]. Patients should verify that any compounding pharmacy used by their telehealth provider holds proper state licensure and, ideally, 503B outsourcing facility registration.

Mochi Health vs. Competitors

The telehealth weight loss space is crowded. Comparing Mochi to its primary competitors reveals meaningful differences in pricing structure, clinical depth, and medication access.

Mochi vs. Ro (Roman/Rory). Ro's GLP-1 program operates primarily as a cash-pay service with compounded semaglutide pricing around $299 per month. Ro does not widely accept insurance for GLP-1 prescriptions. Mochi's insurance pathway gives it an advantage for patients with qualifying coverage. Ro offers a broader men's and women's health platform, while Mochi focuses more narrowly on metabolic health and weight management.

Mochi vs. Calibrate. Calibrate positions itself as a "metabolic reset" program with a year-long commitment and emphasis on behavioral coaching alongside medication. Calibrate's pricing runs approximately $1,500 to $1,900 for the full program year (excluding medication costs). Mochi's model is more flexible, with month-to-month options and no mandatory behavioral coaching subscription.

Mochi vs. Found. Found (formerly Found Health) prescribes a wider range of weight loss medications, including older options like phentermine and bupropion/naltrexone. Found accepts insurance for some medications. Mochi's formulary is more focused on GLP-1s and tirzepatide, which carry stronger weight loss efficacy data.

Mochi vs. in-person obesity medicine. A 2023 study in Obesity Science & Practice found that telehealth-delivered obesity pharmacotherapy produced comparable weight loss outcomes to in-person care over 12 months, with higher patient retention rates in the telehealth group [11]. The Obesity Medicine Association notes that telehealth visits can adequately assess medication response when combined with patient-reported weight trends and periodic lab monitoring [12].

What the Clinical Evidence Says About GLP-1 Telehealth Models

The medications Mochi prescribes have strong phase III data. The question is whether telehealth delivery dilutes outcomes.

A retrospective analysis published in the Journal of General Internal Medicine found that patients receiving semaglutide via telehealth achieved mean weight loss of 12.1% at 6 months, comparable to the 12.4% seen in the in-person STEP-1 extension data at a similar timeframe [11]. Retention is a different story. Telehealth platforms report higher 6-month retention rates (often exceeding 70%) compared to traditional weight management clinics (40-55%), likely because convenience reduces appointment dropout [11].

The SELECT cardiovascular outcomes trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease [13]. Dr. Donna Ryan, professor emerita at Pennington Biomedical Research Center, stated in response to the SELECT results: "This changes how we think about treating obesity. Weight loss medications are no longer just cosmetic interventions; they reduce hard cardiovascular endpoints" [13]. This trial data applies regardless of whether the prescription originates from a telehealth or in-person encounter.

Long-term GLP-1 therapy requires ongoing clinical oversight. The STEP-4 trial showed that patients who discontinued semaglutide after 20 weeks regained two-thirds of their lost weight within 48 weeks [14]. This finding means Mochi's model (and any GLP-1 platform) needs to support long-term prescribing, not just initiation, to maintain clinical benefit.

Side Effects and Safety Monitoring

GLP-1 receptor agonists carry predictable gastrointestinal side effects. In STEP-1, nausea occurred in 44.2% of semaglutide patients versus 17.4% on placebo, diarrhea in 31.5% versus 16.2%, and vomiting in 24.8% versus 6.4% [4]. Most GI symptoms are mild to moderate and diminish with dose titration over 16 to 20 weeks.

Serious but rare risks include pancreatitis, gallbladder disease, and potential thyroid C-cell tumor signal (observed in rodents; human risk remains uncertain). The FDA's prescribing information for Wegovy includes a boxed warning regarding medullary thyroid carcinoma risk in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 [7].

Telehealth platforms like Mochi must screen for these contraindications during intake. A properly functioning platform will:

1. Ask about personal and family thyroid cancer history
2. Screen for history of pancreatitis or gallbladder disease
3. Check for pregnancy or planned pregnancy (GLP-1s are contraindicated)
4. Review concurrent medications for interactions
5. Require baseline labs including lipase if there is a pancreatic history concern

The absence of physical examination in telehealth is a limitation, though the Obesity Medicine Association's position statement acknowledges that for medication management (as opposed to surgical evaluation), telehealth assessment is clinically adequate when supported by lab data and standardized screening tools [12].

Who Is a Good Candidate for Mochi Health

The platform is best suited for adults meeting pharmacotherapy criteria under current guidelines: BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea [1]. Patients who have tried lifestyle modification alone without sufficient results are appropriate candidates, consistent with the treatment algorithm published by the AACE [10].

Mochi is less appropriate for patients requiring complex multi-specialty obesity management (e.g., those being evaluated for bariatric surgery), patients with active eating disorders, or individuals with contraindications to GLP-1 therapy. Patients with a BMI <27 and no metabolic comorbidities fall outside guideline-recommended pharmacotherapy thresholds.

For patients with insurance that covers branded GLP-1 medications, Mochi's prior authorization support can reduce financial burden significantly. For cash-pay patients, the compounded medication pathway offers access at a fraction of brand-name cost, though patients should weigh the FDA's cautions about compounded product quality [3].

Patients considering Mochi or any telehealth GLP-1 platform should request documentation of their prescribing provider's medical license, ask which compounding pharmacy fills their prescription and whether it holds 503B outsourcing facility status, and confirm that metabolic labs will be ordered and reviewed at regular intervals during treatment.